외분비 췌장 기능부전 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Exocrine Pancreatic Insufficiency Market size is expected to reach USD 6.23 Billion in 2034 from USD 3.69 Billion (2025) growing at a CAGR of 5.99% during 2026-2034.

The global exocrine pancreatic insufficiency market is growing steadily due to the increasing prevalence of digestive disorders and pancreatic diseases. Exocrine pancreatic insufficiency occurs when the pancreas does not produce enough digestive enzymes, leading to poor nutrient absorption. Rising awareness about gastrointestinal health and improved diagnostic capabilities are encouraging more patients to seek treatment, contributing to market growth.

A key driver of this market is the increasing incidence of conditions such as chronic pancreatitis, cystic fibrosis, and pancreatic cancer. These diseases often result in enzyme deficiencies that require enzyme replacement therapies. Pharmaceutical companies are also focusing on developing more effective pancreatic enzyme replacement treatments, which is further boosting the market.

In the coming years, the market is expected to expand as healthcare systems focus more on early diagnosis and improved treatment options. Advancements in drug formulations and growing access to healthcare services in developing regions will likely support market expansion. Additionally, ongoing clinical research aimed at improving digestive enzyme therapies will create new opportunities in the exocrine pancreatic insufficiency treatment landscape.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment

• Nutritional Management
• Pancreatic Enzyme Replacement Therapy (PERT)

By Drug Type

• Creon
• Zenpep
• Pancreaze
• Viokace
• Other Drug Types

By Symptom

• Abdominal Pain
• Constipation
• Diarrhea
• Fatty Stools
• Weight Loss
• Other Symptoms

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Abbott Laboratories, AbbVie, Digestive Care, Essential Pharma, Nestle, Nordmark Pharma, Sun Pharmaceutical Industries, Viatris, Vivus, Zentiva Pharma UK
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET: BY TREATMENT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment
• 4.2. Nutritional Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Pancreatic Enzyme Replacement Therapy (PERT) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Type
• 5.2. Creon Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Zenpep Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Pancreaze Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Viokace Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Drug Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET: BY SYMPTOM 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Symptom
• 6.2. Abdominal Pain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Constipation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Diarrhea Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Fatty Stools Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Weight Loss Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Other Symptoms Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Treatment
  • 8.2.2 By Drug Type
  • 8.2.3 By Symptom
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Treatment
  • 8.3.2 By Drug Type
  • 8.3.3 By Symptom
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Treatment
  • 8.4.2 By Drug Type
  • 8.4.3 By Symptom
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Treatment
  • 8.5.2 By Drug Type
  • 8.5.3 By Symptom
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Treatment
  • 8.6.2 By Drug Type
  • 8.6.3 By Symptom
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Abbott Laboratories
  • 10.2.2 AbbVie
  • 10.2.3 Digestive Care
  • 10.2.4 Essential Pharma
  • 10.2.5 Nestle
  • 10.2.6 Nordmark Pharma
  • 10.2.7 Sun Pharmaceutical Industries
  • 10.2.8 Viatris
  • 10.2.9 Vivus
  • 10.2.10 Zentiva Pharma UK